Objective: To investigate secretory phospholipase A 2 (sPLA 2 ) activity in neonatal sepsis.
Introduction
Bacterial infection in newborn infants is often complicated by a fulminant sepsis, which has high mortality. 1 Newborn infants, in particular preterm infants, are susceptible to development of sepsis due to their immature microbiological barrier and their limited innate and specific immunity. Nevertheless, bacterial infection elicits an immune response in these infants 2 and activated immune cells, for example, neutrophils, secrete inflammatory mediators, such as interleukin-6 (IL-6), in the local environment or blood stream. IL-6 induces an acute phase response, with C-reactive protein (CRP) and more inflammatory mediators being produced and released into the circulation. This response may not only kill bacteria, but could also be excessive and lead to systemic inflammation and multiple organ failure, the major cause of mortality in septic patients. 3, 4 More insight into the pathogenesis of sepsis in newborn infants is needed so that more specific therapy can be developed and outcome improved. One research avenue would be to investigate various components of the inflammatory cascade. 4, 5 Phospholipase A 2 (PLA 2 ) may be an attractive candidate for study since its plasma concentration and activity is increased in adults with sepsis. [6] [7] [8] Several new PLA 2 inhibitors are currently being studied in adults with sepsis. 9 In humans, cytosolic PLA 2 (cPLA 2 ), calcium 2 þ -independent PLA 2 and secretory PLA 2 (sPLA 2 ) forms of PLA 2 have been identified. 8, 9 PLA 2 catalyzes the rate-limiting step in formation of inflammatory lipid mediators, for example, eicosanoids and platelet activating factor, by hydrolyzing membrane phospholipids and releasing their precursors arachidonic acid (AA) and a lysophospholipid. AA is metabolized by cyclo-oxygenase and lipoxygenase enzymatic pathways to produce eicosanoids, including prostaglandins and leukotrienes. These substances are involved in inflammatory processes. 8, 9 cPLA 2 mainly controls intracellular eicosanoid metabolism. sPLA 2 is an acute phase protein which plays a major role in inflammatory diseases by controlling extracellular eicosanoid production. sPLA 2 can destroy bacteria through hydrolysis of their membrane lipids, and disturb surfactant function through hydrolysis of their phospholipid bilayer. 8, 10, 11 In adults, sPLA 2 is proposed as a sensitive marker for sepsis, and increased plasma levels of sPLA 2 are associated with development of multiple organ failure, vascular dilatation during shock and death. 6, 7, 12 The role of sPLA 2 in neonatal sepsis is unknown and its levels and relationship with well-recognized markers of inflammation have not been investigated.
The objective of this study was to measure sPLA 2 activity in plasma from (pre)term infants with sepsis and compare sPLA 2 with recognized markers of inflammation, such as CRP, immature/total neutrophil ratio and (IL-6).
Methods

Patients
One hundred and fifty-six newborn infants, consecutively admitted to the neonatal intensive care unit during a 6-month period, were included in the study. After admission, blood was routinely drawn for a complete blood count and CRP measurement. If the attending physician suspected an infection, blood samples were also obtained for a complete blood count and CRP, and blood, cerebrospinal fluid and, in ventilated infants, tracheal aspirates were cultured prior to antibiotic therapy. The study period included the first week of life.
Clinical data from mothers and infants were obtained from their charts. The infants were classified as proven sepsis (n ¼ 24), suspected infection (n ¼ 77) and controls (n ¼ 55). Infants in the sepsis group had a positive blood culture. Infants in the suspected infection group had a sterile blood culture in the presence of clinical symptoms of infection (for example, apnea, temperature instability, feeding intolerance). 13 Controls were infants without clinical signs of infection.
Infants with rhesus hemolytic disease or congenital abnormalities were excluded. Three infants were excluded because of a maternal group B streptococcal infection. The hospital's ethics committee reviewed and approved the study. Informed consent was obtained from parents' prior to study.
Peripheral blood samples
The blood samples for hematological analysis were directly sent to the laboratory for further analysis, samples for biochemical analysis were centrifuged within 1 h after collection (10 min, 750 g) and plasma stored under argon at À80 1C.
Measurement of inflammatory factors
The activity of sPLA 2 was measured by hydrolysis of 2-3 H-linoleylphosphatidyl-ethanolamine 14 and CRP concentration by immunoturbidimetric assay (detection limit 0.3 mg l À1 ). 15 The leukocyte count (corrected for the number of nucleated red cells) was determined in the hematology laboratory and immature/total neutrophil (I/T) ratio calculated. To correlate sPLA 2 activity with the concentrations of an established acute phase protein, IL-6 was measured in samples from which a sufficient amount of plasma for measurement by enzyme-linked immunosorbent assay remained (n ¼ 29, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, the Netherlands, detection limit 3 ng l À1 ). IL-6 levels above the highest standard concentrations (46 000 ng l À1 ) were not further quantified. The laboratory technicians were not aware of the infant's clinical condition.
Statistical analysis
From the sepsis and suspected infection groups, we analyzed blood samples taken after onset of clinical symptoms, and from the control group, we analyzed samples routinely taken upon admission. sPLA 2 activity, CRP and IL-6 concentrations, leukocyte count and I/T ratio were non-normally distributed and are expressed as median (min, max) values. Differences between groups were assessed by nonparametric tests (Mann-Whitney) and adjusted for gestational age and Apgar score at 5 min through logistic regression analysis. Differences in characteristics of mothers or infants between groups were assessed by w 2 -test. Correlations between the levels of different factors were expressed by Spearman's correlation coefficient (r).
Receiver operating characteristic (ROC) curves were made to evaluate the performance of the factors for diagnosis of a (culture proven) sepsis or a suspected infection (clinical sepsis without positive blood cultures) at various cutoff values. An area under the curve (AUC) closer to one indicates greater diagnostic power, while an AUC close to 0.5 (the line of nondiscrimination) denotes no diagnostic potential. For sPLA 2 , the cutoff value was determined at the point on the ROC curve where maximal sensitivity consistent with a specificity of at least 50% is achieved, 16 for CRP and I/T ratio, the sensitivity and specificity were determined at a cutoff value of >10 mg l À1 and >0.2, respectively. A P-value (two tailed) <0.05 was considered statistically significant. Analyses were performed using the SPSS package (SPSS for Windows 12.0).
Results
Characteristics of the study population
The majority of infants (151 out of 157) were preterm. In the control group, prematurity was caused by induction of labor for maternal (pre)eclampsia in 16 cases, and 17 mothers received antibiotics for a suspected infection (fever of unknown origin, prolonged rupture of membranes) (P<0.01 suspected infection vs control). The maternal characteristics are summarized in Table 1 .
Except for cord blood pH (P<0.05 suspected infection vs control), infant characteristics, morbidity and mortality were similar in all groups (Table 2) . Early onset sepsis (<72 h after birth) occurred in eight infants and late onset sepsis in 16 infants. Blood cultures in the early onset group showed coagulase-negative staphylococci (n ¼ 4), Escherichia coli (n ¼ 2), Streptococcus pneumoniae (n ¼ 1) and Burkholderia pseudomallei (n ¼ 1), and in the late onset group coagulase-negative staphylococci (n ¼ 9), Staphylococcus aureus (n ¼ 3), S. pneumoniae (n ¼ 2), E. coli (n ¼ 1) and Bacillus cereus (n ¼ 1).
Measurement of inflammation markers
Maternal characteristics, such as (pre)eclampsia, use of steroids or antibiotics, and neonatal characteristics such as gender, Apgar score, postnatal age and early or late onset sepsis did not influence the levels of the inflammation markers. In the control group, the levels did not differ between the 17 infants whose mothers had received antibiotics antenatally and the remaining infants.
When all infants (sepsis, suspected infection and controls) were combined, sPLA 2 activity positively correlated to gestational age (r ¼ 0.41, P<0.01), CRP and IL-6 concentrations and I/T ratio (r ¼ 0.678, P<0.01; r ¼ 0.575, P<0.01; r ¼ 0.528, P<0.01).
Plasma sPLA 2 activity, CRP concentration and I/T ratio were significantly higher in the sepsis group than in the suspected infection and control groups (P<0.01). In the suspected infection group, sPLA 2 activity, CRP concentration and I/T ratio were significantly higher than those in the control group (P ¼ 0.05; P ¼ 0.05 and P<0.01, respectively). IL-6 concentration was significantly higher in the sepsis group than in the control group, but the difference with the suspected infection group and the difference between the suspected infection and control groups were not statistically significant (sepsis vs control, P ¼ 0.01, Table 3 ). sPLA 2 activity in plasma was positively correlated to the total duration of oxygen supplementation infants received during hospitalization (r ¼ 0.30, P<0.01). Infants with respiratory distress syndrome (RDS) had higher sPLA 2 activity than infants who developed bronchopulmonary dysplasia (BPD) (median (minimum, maximum) activity in RDS: 2.2 (0.0, 190.2), BPD: 2.3 (0.0, 11.1), infants without RDS or BPD: 2.5 (0.0, 30.6) nmol ml À1 per hour, RDS vs BPD P ¼ 0.02, RDS vs controls P ¼ 0.09).
In the whole group, nine infants had very high sPLA 2 activity (defined as levels >25 nmol ml À1 per hour). Seven infants had RDS, and only two were without respiratory distress. In the sepsis group, four infants with sPLA 2 activity of 40.5, 42.2, 60.6 and 190.2 nmol ml À1 per hour, respectively, had RDS, and one infant with an activity of 29.6 nmol ml À1 per hour had no RDS. In the suspected infection group, three infants had RDS and sPLA 2 activity of 25.4, 74.3 and 112.3 nmol ml À1 per hour, respectively, and one infant with an activity of 30.6 nmol ml À1 per hour had no RDS. In the control group, all levels were lower than 25 nmol ml À1 per hour. Because of a small number of measurements, IL-6 concentrations in RDS and BPD infants could not be compared. None of the infants with plasma sPLA 2 activity higher than 25 nmol ml À1 per hour developed BPD later on and sPLA 2 activity was not higher in infants with major complications, such as intraventricular hemorrhage or death.
Diagnostic performance of the inflammation markers
Except for the leukocyte count, all ROC curves differed significantly from the line of nondiscrimination (P<0.01). The ROC curve of IL-6 was not calculated because of the low number of measurements in the whole group (n ¼ 29). Irrespective of how groups were compared, CRP had a greater AUC and thus greater diagnostic power than sPLA 2 or I/T ratio, and sPLA 2 had a greater AUC than I/T ratio ( Table 4 ). The AUC's of all inflammation markers were highest when sepsis and control groups were compared, intermediate AUC's were found when the sepsis group was compared with suspected infection and control groups, and the lowest AUC's were found when sepsis and suspected infection groups were compared with controls ( Table 4 ). The latter is clinically the most relevant comparison, between infants who are ill and healthy infants. In all three comparisons, the sensitivity of sPLA 2 and CRP were roughly similar, but the specificity of sPLA 2 was lower than that of CRP. The sensitivity and specificity of sPLA 2 were higher than that of I/T ratio (Table 4) .
Discussion
This study showed increased sPLA 2 activity in plasma from newborn infants with a suspected infection and sepsis. sPLA 2 activities were highest when infants also had RDS.
Increased sPLA 2 concentrations up to 500-fold have been reported in plasma from adults with sepsis, 6 whereas in this study sPLA 2 activity in newborn plasma samples increased approximately 15-fold. Immaturity of important sources of sPLA 2 , for example, hepatocytes 17 and neutrophils, 9 may have led to lower sPLA 2 production. Early blood sampling during the acute phase response may also have contributed to this lower increase in sPLA 2 activity, or possibly anti-inflammatory cytokines (for example, TGFb and IL-10) played a role in these ill infants by reducing the expression of sPLA 2 in plasma. 9 sPLA 2 binding to soluble and membrane bound G-proteincoupled receptors on the neutrophil's membrane induces cellular responses, such as cell movement and production of superoxide radicals and elastase enzymes. [18] [19] [20] Besides receptor-binding, sPLA 2 can hydrolyze the neutrophil membrane lipids and release precursors of lipid mediators, which act as intracellular second messengers leading to neutrophil migration and, in the extracellular compartment, may cause vasoconstriction or dilatation. 9,18 -20 In vivo, sPLA 2 contributed to ischemiareperfusion injury of rat kidneys through induction of neutrophil infiltration, 21 and in a rabbit ARDS model it induced pulmonary neutrophil influx via leukotriene B 4 production. 22 Taken together, one might assume that increased sPLA 2 activity in septic infants leads to neutrophil migration and production of inflammatory eicosanoids, radicals and enzymes. 8, 9 This may cause bacterial destruction, but could also aggravate the inflammatory response in sepsis. Lipid mediators derived not only from the neutrophil's membrane, but also from bacterial cell or from other cell membranes by action of sPLA 2 may further stimulate the inflammatory process.
11 CRP may amplify the inflammatory effects of sPLA 2 . In inflamed tissues, CRP binds to cell membranes which contain many lysophospholipids due to sPLA 2 activity, and activate complement via the classical pathway. 23 In adults with ARDS, sPLA 2 activity in blood and lungs is increased and surfactant phospholipids are destroyed. 9, 10 In this study, plasma sPLA 2 activity was positively correlated with duration of oxygen supplementation and significantly increased in infants with RDS, whereas no correlation with development of BPD was found. Possibly infants with the highest sPLA 2 activity in plasma had high pulmonary sPLA 2 activity as well, resulting in RDS due to surfactant phospholipid hydrolysis. Other factors, that is, increase of inflammatory cytokines seen in infants with RDS, 24 may have induced production of sPLA 2 from cells, for example, neutrophils, leading to higher plasma sPLA 2 activity. 9 Because of limited sample material, we could not reliably compare the measured IL-6 concentrations between RDS and BPD infants, and confirm earlier findings of increased IL-6 in these infants.
Although we did not find a correlation between sPLA 2 activity levels and mortality, as was found in adults, 6 ,7 based on our findings of increased sPLA 2 activity in RDS, we cannot exclude the possibility that increased sPLA 2 activity levels induce a systemic inflammatory response in these infants, which may lead to RDS, septic shock and even death. 6, 7 The timing of blood sampling may have been too early into the acute phase response, or the number of infants in this study may have been too small to detect such a relationship. Early diagnosis and antimicrobial treatment of sepsis remains the best strategy in neonatal practice, but requires sensitive markers of inflammation. Indicators such as CRP, white blood cell count and I/T ratio do not have high sensitivity, especially if measured very early in the course of sepsis. 25 Cytokines, such as IL-6, are currently considered to be the best early inflammation markers since their concentrations increase earlier, but decline rapidly and may lead to peak concentrations being missed. 16, 26, 27 Due to logistic reasons, we could not compare sPLA 2 , CRP and I/T ratio with IL-6. sPLA 2 was proposed as a sensitive marker of sepsis in adults as sPLA 2 reflects earlier biological events than CRP and the concentration declines earlier. 12, 27 In this study, the diagnostic performance of sPLA 2 for suspected infection and sepsis was less than that of CRP, and better than I/T ratio. In clinical practice, newborn infants with clinical signs of infection receive antibiotics even when laboratory investigations are not suggestive of bacterial infection. Except for a diagnostic marker with sensitivity and specificity of almost 100%, it is unlikely that any new marker, such as sPLA 2 , will change this policy. Since the specificity of sPLA 2 is low (52 vs 67% for CRP and 72% for I/T ratio for infants with sepsis and suspected infection, Table 4 ), we cannot answer the question whether it is safe to withhold antibiotic treatment in infants with normal sPLA 2 activity.
In adults with sepsis, plasma sPLA 2 concentration strongly correlates with activity, 6 and this needs to be assessed in newborn infants. The radioactive method we used is not suitable for routine clinical use, so easier methods for sPLA 2 concentration measurements should be developed and tested. The results of these studies will allow us to further investigate whether increased sPLA 2 levels are correlated to increased severity of the inflammatory response.
Improved therapies are needed in infants who have severe sepsis and do not respond well to treatment. In adults with sepsis, treatment strategies inhibiting the systemic inflammatory response have not shown a large effect on outcome, but this has not been tested in infants. 5 Until now, results of anti-tumor necrosis factor antibodies or IL-1 receptor antagonists therapy have been disappointing in sepsis in adults. 5 However, inhibitors of sPLA 2 decrease inflammation and increase survival in animal models of septic shock. 22, 28, 29 sPLA 2 inhibitors have been tested in adults with sepsis and other inflammatory diseases, but the results are disappointing. 9, 27, 30 This is probably related to the functional diversity of sPLA 2 , with a function in cell homeostasis, and proand even anti-inflammatory roles under certain circumstances. Attempts to develop suitable PLA 2 inhibitors for the treatment of inflammatory diseases have yet to succeed and new sPLA 2 inhibitors are being tested. 9 Inhibition of the inflammatory response in preterm infants is an even greater challenge and could act as a double-edged sword by compromising their limited immune response by decreasing bacterial membrane hydrolysis and neutrophil migration and, therefore, abundant blocking may be inappropriate.
In conclusion, plasma sPLA 2 activity is increased in neonatal sepsis and sPLA 2 activity is highest in infants who also have RDS. Further studies are needed to assess the effect of sPLA 2 inhibition in septic newborn infants, especially those unresponsive to current treatments.
